CCDC14 Activators
CCDC14 Activators are a class of compounds that enhance the functional activity of CCDC14 through various specific biochemical and cellular pathways. These activators work by enhancing the phosphorylation state of proteins that interact with CCDC14, altering the localization or conformation of CCDC14 to increase its functional activity, or by modulating the signaling pathways that CCDC14 is involved with. For example, Forskolin is known to elevate intracellular cAMP, thus enhancing protein kinase A (PKA) activity. PKA can phosphorylate various substrates that may be involved in the regulation of CCDC14 activity, thereby enhancing the overall function of CCDC14. Similarly, PMA activates protein kinase C (PKC), which is known to phosphorylate a wide range of target proteins. PKC-mediated phosphorylation can alter the function of proteins that directly or indirectly associate with CCDC14, leading to an increase in its activity.
Further, IBMX acts to inhibit the breakdown of cAMP, thus sustaining the activation of PKA and prolonging its effects on CCDC14 function. EGF, through its receptor EGFR, launches a cascade of phosphorylation events within the cell that can culminate in the modification of proteins interacting with CCDC14, which in turn enhances CCDC14's activity. Insulin triggers the PI3K/Akt pathway, which regulates numerous cellular functions; this signaling can lead to the activation of downstream proteins that enhance the functional activity of CCDC14.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Adenylyl cyclase activator that increases cAMP levels, enhancing PKA activity which can phosphorylate proteins associated with CCDC14, thus potentially increasing CCDC14 functional activity. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PKC activator which can phosphorylate intermediates that interact with CCDC14, leading to its enhanced activity. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
Phosphodiesterase inhibitor that prevents cAMP breakdown, thereby sustaining PKA activity which can enhance CCDC14 activity through phosphorylation of associated proteins. | ||||||
Insulin | 11061-68-0 | sc-29062 sc-29062A sc-29062B | 100 mg 1 g 10 g | $156.00 $1248.00 $12508.00 | 82 | |
Activates the insulin receptor pathway, leading to PI3K/Akt activation, which can enhance CCDC14 activity through downstream signaling effects. | ||||||
FTY720 | 162359-56-0 | sc-202161 sc-202161A sc-202161B | 1 mg 5 mg 25 mg | $33.00 $77.00 $120.00 | 14 | |
Sphingosine-1-phosphate receptor modulator that can activate signaling pathways affecting CCDC14 activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
PI3K inhibitor that can lead to alterations in downstream signaling, indirectly enhancing CCDC14 activity by modulating interacting pathways. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
p38 MAPK inhibitor that can alter the activity of kinases that modulate CCDC14 functional activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
MEK inhibitor that indirectly enhances CCDC14 activity by affecting the MAPK/ERK pathway which interacts with CCDC14-associated signaling. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $80.00 $220.00 $460.00 | 64 | |
Activates SIRT1 which can deacetylate proteins in pathways interacting with CCDC14, enhancing its activity. | ||||||